In This Article:
-
Rytelo Net Product Revenue (Q4 2024): $47.5 million.
-
Rytelo Net Product Revenue (Full Year 2024): $76.5 million.
-
Total Net Revenue (Q4 2024): $47.5 million.
-
Total Net Revenue (Full Year 2024): $77 million.
-
Cash Position (End of 2024): Approximately $503 million.
-
Total Operating Expenses (Q4 2024): $67.6 million.
-
Total Operating Expenses (Full Year 2024): $250.7 million.
-
Cost of Goods Sold (Q4 2024): Approximately $783,000.
-
Cost of Goods Sold (Full Year 2024): $1.3 million.
-
Research and Development Expenses (Q4 2024): $23.4 million.
-
Research and Development Expenses (Full Year 2024): $103.7 million.
-
Selling, General and Administrative Expenses (Q4 2024): $43.4 million.
-
Selling, General and Administrative Expenses (Full Year 2024): $145.7 million.
-
Expected Operating Expenses (Fiscal Year 2025): $270 million to $285 million.
Release Date: February 26, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Geron Corp (NASDAQ:GERN) achieved FDA approval for Rytelo in June 2024, marking a significant milestone for the company.
-
Rytelo received favorable placement in the MDS NCCN guidelines, including a Category 1 treatment recommendation.
-
The company reported $47.5 million in Rytelo net product revenue in Q4 2024, exceeding internal expectations.
-
Geron Corp (NASDAQ:GERN) ended the year with a strong cash position of approximately $503 million, which is expected to support profitability without additional financing.
-
The Phase III IMpactMF trial for imetelstat in myelofibrosis is 80% enrolled, with potential to transform treatment for relapsed/refractory myelofibrosis patients.
Negative Points
-
Despite initial success, Geron Corp (NASDAQ:GERN) observed flat revenue trends for Rytelo over the last few months.
-
The majority of new patient starts for Rytelo have been in the third-line plus segment, with lower than expected starts in the second line.
-
There is variability in regional and account-level performance, indicating inconsistent uptake across different territories.
-
The company had to change its commercial and medical affairs leadership a few months into the Rytelo launch, indicating potential initial missteps.
-
Geron Corp (NASDAQ:GERN) has not provided specific revenue guidance for 2025, citing the need for more quarters of data to establish reliable forecasts.
Q & A Highlights
Q: Can you provide insights on the recent revenue trends and expectations for the first quarter of 2025? A: Jim Ziegler, Executive Vice President and Chief Commercial Officer, noted that revenues have shown variability week-over-week, but the four and eight-week rolling averages indicate flatness. This trend continued into the period leading up to the call. It's too early to make a definitive call on Q1 revenues, but the past few months have been relatively flat.